Skip to content

Mark Haden

7 papers in the library · 39 citations · publishing 2016-2026

Papers

Sort Most recent Most cited

Psychedelics and longevity: implications for lifespan, healthspan and functional aging

Longevity July 5, 2026 Mark Haden, Birgitta Woods, Tina Woods et al.

Longevity science has increasingly shifted its focus from extending lifespan to improving healthspan, the years lived in good physical, cognitive, and social health. While much research targets biological hallmarks of aging, emerging frameworks emphasize upstream psychosocial drivers such as chronic stress, trauma, social isolation, and health behavior. In parallel, research on psychedelic...

DOI: 10.1080/30653495.2026.2696224 (opens in new tab) Senescence Nervous system Disease

Beyond prohibition: A public health analysis of naturalistic psychedelic use

Journal of Psychedelic Studies July 3, 2025 Mark Haden, Sarah A. Paschall, Birgitta Woods 2 citations

Abstract Psychedelic drug use is experiencing a global resurgence, both in clinical research and community settings. This paper presents a comprehensive public health analysis of the naturalistic use of psychedelics—defined as use outside clinical or research environments. Drawing on a review of 104 peer-reviewed articles, this analysis evaluates the mental, physical, and social outcomes...

DOI: 10.1556/2054.2025.00450 (opens in new tab) Naturalism Public health Criminology Psychoanalysis

Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.

Psychedelic Medicine September 1, 2024 Michelle St Pierre, Lucas Standing, Yarissa Herman et al. 3 citations

A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced growing attention in the past decade and may be an increasing topic of patient-physician interactions. The stigmatization of psychedelic use may complicate this process. However, patient...

DOI: 10.1089/psymed.2023.0060 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Barriers to access Physician communication Plant medicine +5

Psychedelics and schizophrenia: A mystery in history

Journal of Psychedelic Studies December 2, 2023 Mark Haden, Birgitta Woods, Sarah A. Paschall 3 citations

Abstract This analysis of current and historical research and clinical reports observes that the relationship between psychedelics and schizophrenia is complex and there are reports of psychedelics benefiting this population. Specifically, lower doses of psychedelics (mostly LSD) appear to have a potential beneficial impact on the negative symptoms of schizophrenia.

DOI: 10.1556/2054.2023.00277 (opens in new tab) Full text (opens in new tab) Schizophrenia object-oriented programming Population Clinical psychology

LSD Overdoses: Three Case Reports

Journal of Studies on Alcohol and Drugs 2020 Mark Haden, Birgitta Woods 31 citations

OBJECTIVE: In academic settings around the world, there is a resurgence of interest in using psychedelic substances for the treatment of addictions, posttraumatic stress disorder, depression, anxiety, and other diagnoses. This case series describes the medical consequences of accidental overdoses in three individuals. METHOD: Case series of information were gathered from interviews, health...

MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance.

Substance Use & Misuse January 28, 2017 Mark Haden, John R H Archer, Paul I Dargan et al.

MDMB-CHMICA (methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate) is a synthetic cannabinoid receptor agonist that has been detected in several recreational drug products in Europe since August 2014. This article aims to describe the prevalence of use, availability, and desired and adverse effects of MDMB-CHMICA. Data were collated from published scientific literature,...

DOI: 10.1080/10826084.2016.1223692 (opens in new tab) Full text (opens in new tab) Mdmb-chmica Nps Recreational drugs Synthetic cannabinoid +1

A Public-Health-Based Vision for the Management and Regulation of Psychedelics.

Journal of Psychoactive Drugs 2016 Mark Haden, Brian Emerson, Kenneth W. Tupper

The Health Officers Council of British Columbia has proposed post-prohibition regulatory models for currently illegal drugs based on public health principles, and this article continues this work by proposing a model for the regulation and management of psychedelics. This article outlines recent research on psychedelic substances and the key determinants of benefit and harm from their use. It...

DOI: 10.1080/02791072.2016.1202459 (opens in new tab) Full text (opens in new tab) Drug policy Drug regulation Psychedelic Psychoactive +1